KIAA1109 Inhibitors
KIAA1109 inhibitors encompass a range of chemical compounds that interfere with various signaling pathways potentially relevant to the protein's function. For instance, compounds like PD98059 and U0126 act specifically as MEK inhibitors, thereby preventing the activation of the MAPK/ERK pathway, which is pivotal for cell growth and differentiation. The inhibition of this pathway may lead to a subsequent decrease in KIAA1109 activity if it is regulated by this signaling cascade. Similarly, LY294002 and Wortmannin are potent inhibitorsof the PI3K pathway and can halt AKT signaling, which is crucial for cell survival and proliferation. This could lead to reduced activity of KIAA1109 if its functional regulation is linked to PI3K/AKT signaling. Rapamycin, a known inhibitor of the mTOR pathway, could also serve as an indirect inhibitor of KIAA1109 by interfering with cell growth and proliferation signals that might modulate KIAA1109 activity. Other inhibitors, such as SB203580 and SP600125, target the p38 MAP kinase and JNK, respectively, and their inhibition could disrupt inflammatory responses or stress-induced pathways that potentially influence KIAA1109 activity.
Dorsomorphin's ability to inhibit BMP signaling by targeting BMP type I receptors suggests that KIAA1109 activity could also be indirectly reduced if it is involved in BMP pathways. Staurosporine, with its broad kinase inhibition profile, could affect KIAA1109 by inhibiting kinases that may regulate its activity through phosphorylation. Bortezomib, as a proteasome inhibitor, could impact KIAA1109 by inducing cellular stress through the accumulation of misfolded proteins, which may affect related signaling pathways. Dasatinib's broad specificity as a tyrosine kinase inhibitor means it could affect KIAA1109 by inhibiting upstream regulators or direct modulators of the protein. Lastly, Olaparib, a PARP inhibitor affecting DNA repair mechanisms, could lead to decreased KIAA1109 activity if it is associated with DNA damage response signaling, illustrating the diverse biochemical routes through which KIAA1109 inhibitors can operate to decrease the protein's functional activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which indirectly leads to the inhibition of the MAPK/ERK pathway. Since the MAPK/ERK pathway is involved in numerous cellular processes including cell growth and differentiation, inhibition by PD98059 could reduce the activity of proteins, such as KIAA1109, that may be regulated by this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of the phosphoinositide 3-kinases (PI3K), which halts the PI3K/AKT signaling pathway. This pathway is crucial for cell survival and proliferation, and its inhibition by LY294002 can lead to reduced activity of downstream proteins like KIAA1109 if they are reliant on PI3K/AKT signaling for functional regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 MAPK can affect inflammatory cytokine production and cell cycle regulation. If KIAA1109 activity is modulated by p38 MAPK-mediated signaling, SB203580 could be an indirect inhibitor of KIAA1109 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which plays a role in stress-induced apoptosis and immune responses. By inhibiting JNK, SP600125 can disrupt pathways that might modulate the activity of proteins like KIAA1109. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another inhibitor of MEK, similar to PD98059, which also prevents the activation of the MAPK/ERK pathway. Through this inhibition, U0126 could indirectly decrease the functional activity of KIAA1109 if it is regulated by the MAPK/ERK signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, wortmannin can disrupt the PI3K/AKT pathway and potentially inhibit the activity of KIAA1109 if it is dependent on this signaling for its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a well-known inhibitor of the mammalian target of rapamycin (mTOR) pathway, which is involved in cell growth and proliferation. By inhibiting mTOR, rapamycin could indirectly inhibit the activity of KIAA1109 if its function is regulated by mTOR signaling. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsomorphin is an inhibitor of BMP signaling and specifically targets the BMP type I receptors ALK2, ALK3, and ALK6. If KIAA1109 is involved in BMP signaling pathways, its activity could be indirectly inhibited by dorsomorphin. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a non-selective inhibitor of protein kinases. Its broad kinase inhibition profile suggests that it could indirectly inhibit the activity of KIAA1109 if KIAA1109 function involves phosphorylation by specific kinases targeted by staurosporine. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, inducing cellular stress and potentially affecting signaling pathways. If KIAA1109 function is linked to proteasome activity, bortezomib could indirectly inhibit KIAA1109. | ||||||